The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
2-[2-[[3-[4-chloro-2-fluoro-5-[[(3R)-3-piperidyl]oxy]phenyl]-2-fluoro-benzoyl]amino]-5-fluoro-phenyl]acetic acid ID: ALA4751488
PubChem CID: 154585554
Max Phase: Preclinical
Molecular Formula: C26H22ClF3N2O4
Molecular Weight: 518.92
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: O=C(O)Cc1cc(F)ccc1NC(=O)c1cccc(-c2cc(O[C@@H]3CCCNC3)c(Cl)cc2F)c1F
Standard InChI: InChI=1S/C26H22ClF3N2O4/c27-20-12-21(29)19(11-23(20)36-16-3-2-8-31-13-16)17-4-1-5-18(25(17)30)26(35)32-22-7-6-15(28)9-14(22)10-24(33)34/h1,4-7,9,11-12,16,31H,2-3,8,10,13H2,(H,32,35)(H,33,34)/t16-/m1/s1
Standard InChI Key: MOOARNYDOKGVQG-MRXNPFEDSA-N
Molfile:
RDKit 2D
36 39 0 0 0 0 0 0 0 0999 V2000
25.3024 -25.6663 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.3013 -26.4937 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.0161 -26.9066 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.7325 -26.4933 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.7297 -25.6627 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.0143 -25.2535 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.0178 -27.7293 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.3016 -28.1410 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.3010 -28.9653 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.0159 -29.3787 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.7328 -28.9620 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.7299 -28.1392 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.4425 -25.2475 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.1586 -25.6574 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
27.4395 -24.4225 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
26.0169 -30.2037 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
28.8714 -25.2421 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.5859 -25.6553 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.2983 -25.2408 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.2957 -24.4150 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.5746 -24.0053 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.8652 -24.4223 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.5870 -26.4803 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.3020 -26.8919 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.3030 -27.7169 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
31.0159 -26.4785 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
27.4487 -29.3722 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
28.1617 -28.9574 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.8721 -29.3714 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.5831 -28.9600 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
29.5846 -28.1347 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.8689 -27.7224 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.1517 -28.1354 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.0080 -23.9989 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
24.5876 -27.7276 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
27.4477 -26.9046 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 2 0
6 1 1 0
7 8 2 0
8 9 1 0
9 10 2 0
10 11 1 0
11 12 2 0
12 7 1 0
3 7 1 0
5 13 1 0
13 14 1 0
13 15 2 0
10 16 1 0
14 17 1 0
17 18 2 0
18 19 1 0
19 20 2 0
20 21 1 0
21 22 2 0
22 17 1 0
18 23 1 0
23 24 1 0
24 25 2 0
24 26 1 0
11 27 1 0
28 27 1 6
28 29 1 0
28 33 1 0
29 30 1 0
30 31 1 0
31 32 1 0
32 33 1 0
20 34 1 0
8 35 1 0
4 36 1 0
M END Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 518.92Molecular Weight (Monoisotopic): 518.1220AlogP: 5.43#Rotatable Bonds: 7Polar Surface Area: 87.66Molecular Species: ZWITTERIONHBA: 4HBD: 3#RO5 Violations: 2HBA (Lipinski): 6HBD (Lipinski): 3#RO5 Violations (Lipinski): 2CX Acidic pKa: 3.48CX Basic pKa: 9.43CX LogP: 2.85CX LogD: 2.85Aromatic Rings: 3Heavy Atoms: 36QED Weighted: 0.39Np Likeness Score: -0.97
References 1. Velcicky J,Wilcken R,Cotesta S,Janser P,Schlapbach A,Wagner T,Piechon P,Villard F,Bouhelal R,Piller F,Harlfinger S,Stringer R,Fehlmann D,Kaupmann K,Littlewood-Evans A,Haffke M,Gommermann N. (2020) Discovery and Optimization of Novel SUCNR1 Inhibitors: Design of Zwitterionic Derivatives with a Salt Bridge for the Improvement of Oral Exposure., 63 (17): [PMID:32856916 ] [10.1021/acs.jmedchem.0c01020 ]